Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Revol

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Therapie|February 28, 2022
[Pharmacology of cannabidiol: Red flags, consequences and risks in humans]Joëlle Micallef, Anne Batisse, Bruno Revol
Therapie|February 21, 2024
Cannabidiol (CBD): Confronting consumers' expectations of therapeutic benefits with pharmacological realityBruno Revol, Julie Bagnolati, Joëlle Micallef, et al.
Therapie|September 25, 2017
Immunoglobulins: Benefits and risks from the patient's point of viewBruno Revol, Laura Bickert, Françoise Sarrot-Reynauld, et al.
British Journal of Clinical Pharmacology|July 14, 2018
Proton pump inhibitors and Raynaud's phenomenon: is there a link?Charles Khouri, Bruno Revol, Jean-Luc Cracowski, et al.
Therapie|December 14, 2022
[Use CBD or drive, do you have to choose?]Théo Willeman, Joëlle Micallef, Jean-Claude Alvarez, et al.
Therapeutic Advances in Neurological Disorders|September 18, 2024
Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system databaseCharles Khouri, Alex Hlavaty, Bruno Revol, et al.
Sleep|July 8, 2022
Impact of OSA primary therapy on antihypertensive drugs useBruno Revol, Christel Castelli, Marie Joyeux-Faure, et al.
British Journal of Clinical Pharmacology|June 6, 2022
Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance databaseBruno Revol, Maryse Lapeyre-Mestre, Nathalie Fouilhé Sam-Laï, et al.
Pharmacoepidemiology and Drug Safety|November 1, 2018
Impact of the "French Levothyrox crisis" on signal detection in the World Health Organization pharmacovigilance databaseCharles Khouri, Bruno Revol, Marion Lepelley, et al.
Therapie|August 13, 2017
[Convulsions associated with Neocodion<sup>®</sup> abuse (codeine camphosulfonate, sulfogaiacol, grindelia extract)]Bruno Revol, Hannah-Marie Doudoux, Nathalie Fouilhé Sam-Laï, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Therapie|February 28, 2022
[Pharmacology of cannabidiol: Red flags, consequences and risks in humans]Joëlle Micallef, Anne Batisse, Bruno Revol
Therapie|February 21, 2024
Cannabidiol (CBD): Confronting consumers' expectations of therapeutic benefits with pharmacological realityBruno Revol, Julie Bagnolati, Joëlle Micallef, et al.
Therapie|September 25, 2017
Immunoglobulins: Benefits and risks from the patient's point of viewBruno Revol, Laura Bickert, Françoise Sarrot-Reynauld, et al.
British Journal of Clinical Pharmacology|July 14, 2018
Proton pump inhibitors and Raynaud's phenomenon: is there a link?Charles Khouri, Bruno Revol, Jean-Luc Cracowski, et al.
Therapie|December 14, 2022
[Use CBD or drive, do you have to choose?]Théo Willeman, Joëlle Micallef, Jean-Claude Alvarez, et al.
Therapeutic Advances in Neurological Disorders|September 18, 2024
Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system databaseCharles Khouri, Alex Hlavaty, Bruno Revol, et al.
Sleep|July 8, 2022
Impact of OSA primary therapy on antihypertensive drugs useBruno Revol, Christel Castelli, Marie Joyeux-Faure, et al.
British Journal of Clinical Pharmacology|June 6, 2022
Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance databaseBruno Revol, Maryse Lapeyre-Mestre, Nathalie Fouilhé Sam-Laï, et al.
Pharmacoepidemiology and Drug Safety|November 1, 2018
Impact of the "French Levothyrox crisis" on signal detection in the World Health Organization pharmacovigilance databaseCharles Khouri, Bruno Revol, Marion Lepelley, et al.
Therapie|August 13, 2017
[Convulsions associated with Neocodion<sup>®</sup> abuse (codeine camphosulfonate, sulfogaiacol, grindelia extract)]Bruno Revol, Hannah-Marie Doudoux, Nathalie Fouilhé Sam-Laï, et al.
Pageof 6